FVB.129X1(Cg)-Ralgdstm2Cjm/H
| Status | Available to order |
| EMMA ID | EM:12461 |
| International strain name | FVB.129X1(Cg)-Ralgdstm2Cjm/H |
| Alternative name | RalGDS Floxed Mouse |
| Strain type | Targeted Mutant Strains : Conditional mutation |
| Allele/Transgene symbol | Ralgdstm2Cjm |
| Gene/Transgene symbol | Ralgds |
Information from provider
| Provider | Chris Marshall |
| Provider affiliation | The Institute of Cancer Research |
| Genetic information | Conditional knock-out mouse for Ralgds. Mouse Ralgds genomic clones were obtained by screening a 129/SvJ BAC library. A targeting vector was designed using a DNA fragment extending from intron 7 to the 3'UTR, cloned into the pKO scrambler 901 vector. A neomycin cassette flanked by two loxP sites was cloned upstream of exon 16 and a 3rd loxP site was located in exon 8. The exons flanked by loxP sites comprise part of the catalytic domain of Ralgds and residues involved in the binding of the exchange factor to Ras. The construct was electroporated into RW4 ES cells and clones positive for recombination were then transiently transfected with pcrePac vector to eliminate the neomycin cassette. Cells carrying the Ralgds allele lacking exons 9-15 were injected into MF-1 blastocysts and germline-transmitting chimeric mice were obtained. As a result of cre-mediated recombination, a Ralgds floxed allele in which loxP sites flank the exon 9-15 region was obtained. |
| Phenotypic information | Homozygous:No overt phenotype. Ralgds deficiency following cre-mediated recombination in the skin leads to reduced tumour incidence, size and progression to malignancy in skin carcinogenesis driven by Ras.Heterozygous:No overt phenotype. Ralgds deficiency following cre-mediated recombination in the skin leads to reduced tumour incidence, size and progression to malignancy in skin carcinogenesis driven by Ras. |
| Breeding history | Chimera mice with a mixed MF-1/129SvJ background were then backcrossed onto FVB for 6 generations. |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Literature references
- RalGDS is required for tumor formation in a model of skin carcinogenesis.;González-García Ana, Pritchard Catrin A, Paterson Hugh F, Mavria Georgia, Stamp Gordon, Marshall Christopher J, ;2005;Cancer cell;7;219-26; 15766660